AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37643520 — intervention group
Group type: COMPARATOR
Intervention: LDL-C Q3 (2.37-2.93 mmol/L)
Number of subjects: 209
Study 37643520 — intervention group
Group type: COMPARATOR
Intervention: LDL-C Q4 (>2.93 mmol/L)
Number of subjects: 209
Study 37643848 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biomarkers (intestinal fatty acid-binding protein, villin-1, smooth muscle protein 22-alpha) assessed by ELISA
Number of subjects: 120
Study 37643848 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) in exhaled air analyzed by gas chromatography time-of-flight mass spectrometry
Number of subjects: 120
Study 37643848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of AMI based on CT, endovascular and surgical reports, clinical findings, and histopathological examination if applicable
Number of subjects: 120
Study 37643847 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL combined with 3% diquafosol ophthalmic solution (IPL+)
Number of subjects: 360
Study 37643847 — intervention group
Group type: COMPARATOR
Intervention: IPL (active control group)
Number of subjects: 360
Study 37643847 — intervention group
Group type: COMPARATOR
Intervention: DQS (3% diquafosol ophthalmic solution eye-drops) (active control group)
Number of subjects: 360
Study 37643887 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,500 mg of IV semorinemab every 4 weeks for 48 or 60 weeks
Number of subjects: 272
Study 37643887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 37643916 — intervention group
Group type: EXPERIMENTAL
Intervention: Move For Surgery (MFS) program, a home-based and wearable technology-enhanced preconditioning program before lung cancer surgery.
Number of subjects: 102
Study 37643916 — intervention group
Group type: COMPARATOR
Intervention: Usual preoperative care (Control group).
Number of subjects: 102
Study 37644032 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based approach for automating the Fleischner Society's visual score system for emphysema subtyping and severity analysis.
Number of subjects: 9650
Study 37644215 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 134
Study 37644215 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self-rating questionnaires on depressive and somatic symptoms
Number of subjects: 134
Study 37644215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician ratings obtained within structured clinical interviews
Number of subjects: 134
Study 37644215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiomic analyses (genotyping, epigenetics, RNA sequencing, neuron-derived exosomes, purines, immunometabolics)
Number of subjects: 134
Study 37644233 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine (ISA)
Number of subjects: 360
Study 37644354 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT (brief cognitive behavioral therapy)
Number of subjects: 44
Study 37644354 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 44
Study 37644356 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 73
Study 37644356 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 73
Study 37644510 — intervention group
Group type: EXPERIMENTAL
Intervention: Video triage
Number of subjects: 100
Study 37644510 — intervention group
Group type: COMPARATOR
Intervention: Telephone triage
Number of subjects: 100
Study 37644542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy
Number of subjects: 165
Study 37644542 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic septoplasty
Number of subjects: 165
Study 37644556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg IV
Number of subjects: 0
Study 37644556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37644556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0
Study 37644556 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 37644573 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative coronary computed tomographic angiography (CCTA)
Number of subjects: 130
Study 37644573 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (angiography)
Number of subjects: 130
Study 37644651 — intervention group
Group type: EXPERIMENTAL
Intervention: Turtle Program
Number of subjects: 151
Study 37644651 — intervention group
Group type: COMPARATOR
Intervention: Cool Little Kids program (CLK)
Number of subjects: 151
Study 37644732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic tumor volume (MTV) measured using fixed thresholds of SUV
Number of subjects: 0
Study 37644779 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 3802
Study 37644779 — intervention group
Group type: COMPARATOR
Intervention: No tolvaptan use
Number of subjects: 3802
Study 37644869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 0
Study 37644869 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol/betamethasone in combination with NBUVB
Number of subjects: 0
Study 37644980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic regional cerebral oxygenation (rSO2) monitoring during the first 72 hours of continuous kidney replacement therapy or throughout each session of intermittent hemodialysis.
Number of subjects: 11
Study 37644980 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium screening and neurocognitive impairment assessment using the Kinarm robot.
Number of subjects: 11
Study 37645234 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program integrating a healthcare-community partnership (CBEP-HCP) delivered by trained fitness instructors over 12 weeks
Number of subjects: 20
Study 37645234 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program integrating a healthcare-community partnership (CBEP-HCP)
Number of subjects: 20
Study 37645234 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs associated with first-time program implementation
Number of subjects: 20
Study 37645440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led intervention for drug-related problems
Number of subjects: 0
Study 37645440 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 37645455 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Number of subjects: 12
Study 37645472 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home cognitive training tool (NeuroTrackerX) with 10 training sessions over 5 weeks (two times per week)
Number of subjects: 20
Study 37645472 — intervention group
Group type: COMPARATOR
Intervention: In-lab 3D-MOT program (control group) with 20 participants (10 female; mean age = 63.39 years, SD = 12.22)
Number of subjects: 20
Study 37645519 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Teleassistance and Teleconsultation (HBTT) program for three months, including monitoring of vital signs and symptoms.
Number of subjects: 422
Study 37645519 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-HBTT group)
Number of subjects: 422
Study 37645544 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBAP)
Number of subjects: 903
Study 37645544 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing (RVP)
Number of subjects: 903
Study 37645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine at 170 mg/m²
Number of subjects: 9
Study 37645622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine at 100 mg/m²
Number of subjects: 9
Study 37645623 — intervention group
Group type: EXPERIMENTAL
Intervention: GTX-CI (gemcitabine, docetaxel, capecitabine, cisplatin, and irinotecan)
Number of subjects: 0
Study 37645623 — intervention group
Group type: COMPARATOR
Intervention: GTX-C (gemcitabine, docetaxel, capecitabine, and cisplatin)
Number of subjects: 0
Study 37645852 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive optical coherence tomography (OCT) imaging of the eye
Number of subjects: 23
Study 37645940 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote telehealth Transitional Pain Service (TPS) with opioid-tapering CBT protocol
Number of subjects: 86
Study 37646126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 2583
Study 37646126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2583
Study 37646138 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise (5 minutes high intensity)
Number of subjects: 0
Study 37646138 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval exercise (15 minutes high/moderate intervals)
Number of subjects: 0
Study 37646138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study 37646148 — intervention group
Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol
Number of subjects: 80
Study 37646148 — intervention group
Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (prophylaxis)
Number of subjects: 80
Study 37646148 — intervention group
Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (on-demand treatment)
Number of subjects: 80
Study 37646148 — intervention group
Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (for immune tolerance induction)
Number of subjects: 80
Study 37646208 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 3298
Study 37646208 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Number of subjects: 3298
Study 37646214 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair with the MitraClip device plus maximally tolerated guideline-directed medical therapy (GDMT)
Number of subjects: 383
Study 37646214 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 383
Study 37646214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 383
Study 37646262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation support provided through WhatsApp
Number of subjects: 129
Study 37646262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 129
Study 37646398 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37646619 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intensity preference intervention, details not available
Number of subjects: 0
Study 37646619 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 37646657 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen 30 mg plus dexamethasone and daratumumab
Number of subjects: 56
Study 37646657 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen 40 mg plus dexamethasone and daratumumab
Number of subjects: 56
Study 37646657 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone and bortezomib
Number of subjects: 56
Study 37646659 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles)
Number of subjects: 145
Study 37646659 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 145
Study 37646659 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (in patients with CR)
Number of subjects: 145
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 protein detection
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein detection
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 protein high levels
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein detection in t(14;16) cases
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein detection in t(4;14) cases
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D2 presence
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein without 1q gains
Number of subjects: 165
Study 37646661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 and D2 protein undetectability
Number of subjects: 165
Study 37646660 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus daratumumab and dexamethasone
Number of subjects: 54
Study 37646660 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab
Number of subjects: 54
Study 37646664 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab and lenalidomide
Number of subjects: 80
Study 37646670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed, 4-1BB CAR T-cell product administered at a total target dose of 100×10⁶ CAR+ T cells.
Number of subjects: 56
Study 37646670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 56
Study 37646671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-R-CHOP followed by R-HiDAC and R-lenalidomide
Number of subjects: 49
Study 37646676 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis for at least 32 weeks (group 2)
Number of subjects: 133
Study 37646676 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis for at least 24 weeks (groups 3 and 4)
Number of subjects: 133
Study 37646676 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis for at least 24 weeks (group 1)
Number of subjects: 133
Study 37646677 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery at 6 months of age
Number of subjects: 558
Study 37646677 — intervention group
Group type: COMPARATOR
Intervention: Surgery at 12 months of age
Number of subjects: 558
Study 37646678 — intervention group
Group type: EXPERIMENTAL
Intervention: P85-Ab
Number of subjects: 24852
Study 37646678 — intervention group
Group type: COMPARATOR
Intervention: Two-antibody method (EBNA1-IgA and VCA-IgA)
Number of subjects: 24852
Study 37646678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P85-Ab and two-antibody method
Number of subjects: 24852
Study 37646679 — intervention group
Group type: EXPERIMENTAL
Intervention: OTQ923 (CRISPR-Cas9-edited CD34+ HSPC product)
Number of subjects: 3
Study 37646702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezigdomide plus dexamethasone (1.0 mg once daily for 21 days, followed by 7 days off, in each 28-day cycle)
Number of subjects: 101
Study 37646702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezigdomide plus dexamethasone
Number of subjects: 101
Study 37646865 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel cell death tracer
Number of subjects: 6
Study 37646988 — intervention group
Group type: EXPERIMENTAL
Intervention: 8000 IU daily with a loading dose of 50,000 IU
Number of subjects: 0
Study 37646988 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control dose (600 IU daily)
Number of subjects: 0
Study 37646988 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 50,000 IU
Number of subjects: 0
Study 37646988 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index z-score
Number of subjects: 0
Study 37647070 — intervention group
Group type: EXPERIMENTAL
Intervention: LCSDecTool
Number of subjects: 140
Study 37647070 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 140
Study 37647105 — intervention group
Group type: EXPERIMENTAL
Intervention: Minder app (intervention group)
Number of subjects: 1496
Study 37647105 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (control group)
Number of subjects: 1496
Study 37647138 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37647156 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomaterial-enhanced secondary intention healing (SIH)
Number of subjects: 37
Study 37647156 — intervention group
Group type: COMPARATOR
Intervention: Standard secondary intention healing (SIH)
Number of subjects: 37
Study 37647305 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Technique
Number of subjects: 0
Study 37647305 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler Ultrasonography
Number of subjects: 0
Study 37647305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Waveform Analysis
Number of subjects: 0
Study 37647317 — intervention group
Group type: EXPERIMENTAL
Intervention: VRVF device (self-administered remote visual field monitoring)
Number of subjects: 21
Study 37647517 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative household overcrowding
Number of subjects: 3679
Study 37647517 — intervention group
Group type: EXPERIMENTAL
Intervention: Black, Black British, Caribbean, or African ethnicity
Number of subjects: 3679
Study 37647517 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age (ages 50-60 years)
Number of subjects: 3679
Study 37647517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of access to sick pay
Number of subjects: 3679
Study 37647576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus gemcitabine
Number of subjects: 82
Study 37647576 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 82
Study 37647601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibecotamab (XmAb14045) at a target dose of 0.75 μg/kg or higher (n=87)
Number of subjects: 120
Study 37647601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibecotamab (XmAb14045)
Number of subjects: 120
Study 37647633 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24Fc multidose regimen
Number of subjects: 0
Study 37647633 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (placebo)
Number of subjects: 0
Study 37647647 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell product targeting CD19 and CD22
Number of subjects: 12
Study 37647728 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB2450 plus anlotinib 10 mg
Number of subjects: 101
Study 37647728 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB2450 plus anlotinib 12 mg
Number of subjects: 101
Study 37647728 — intervention group
Group type: COMPARATOR
Intervention: TQB2450 plus placebo
Number of subjects: 101
Study 37648112 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified potatoes
Number of subjects: 0
Study 37648112 — intervention group
Group type: COMPARATOR
Intervention: Regular potatoes
Number of subjects: 0
Study 37648263 — intervention group
Group type: EXPERIMENTAL
Intervention: CD39 expression in tumor tissue among NK cells, fibroblasts, and T cells
Number of subjects: 162
Study 37648263 — intervention group
Group type: EXPERIMENTAL
Intervention: CD73 expression in tumor tissue among fibroblasts and Epcam+ cells
Number of subjects: 162
Study 37648263 — intervention group
Group type: EXPERIMENTAL
Intervention: Density of CD39+CD103+CD8+ T cells in tumor nest
Number of subjects: 162
Study 37648345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using new-generation transcatheter heart valves (THVs)
Number of subjects: 201
Study 37648379 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (RBCT)
Number of subjects: 65
Study 37648382 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy
Number of subjects: 519
Study 37648383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g azithromycin
Number of subjects: 34000
Study 37648383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34000
Study 37648393 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal and intrapartum azithromycin
Number of subjects: 49600
Study 37648393 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin administered concurrently with the first and third doses of pentavalent vaccines (Penta-1/3)
Number of subjects: 49600
Study 37648393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49600
Study 37648417 — intervention group
Group type: EXPERIMENTAL
Intervention: Short oral/two-step consent (SOC)
Number of subjects: 108
Study 37648417 — intervention group
Group type: COMPARATOR
Intervention: Deferred consent (DC)
Number of subjects: 108
Study 37648439 — intervention group
Group type: EXPERIMENTAL
Intervention: FACETS+ plus standard care
Number of subjects: 105
Study 37648439 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 105
Study 37648439 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 105
Study 37648579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily in addition to standard of care therapy
Number of subjects: 4000
Study 37648579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 37648977 — intervention group
Group type: EXPERIMENTAL
Intervention: Vega Exercise Community (group-based exercise sessions, 3 times a week for 4 months)
Number of subjects: 400
Study 37648977 — intervention group
Group type: EXPERIMENTAL
Intervention: Vega Exercise Community
Number of subjects: 400
Study 37648977 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 37648990 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT low-score group (score ≤ 5/8)
Number of subjects: 93
Study 37648990 — intervention group
Group type: COMPARATOR
Intervention: CDT high-score group (score ≥ 6/8)
Number of subjects: 93
Study 37648990 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 93
Study 37649005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions with weight-loss
Number of subjects: 2220
Study 37649092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical diaphragmatic stimulation (TEDS)
Number of subjects: 66
Study 37649092 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 66
Study 37649092 — intervention group
Group type: EXPERIMENTAL
Intervention: TEDS
Number of subjects: 66
Study 37649617 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 13000
Study 37649617 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Number of subjects: 13000